×
About 1,060 results

ALLMedicine™ Achondroplasia Center

Research & Reviews  372 results

Fetal autopsy for the diagnosis of skeletal dysplasia and comparison with prenatal ultr...
https://doi.org/10.1515/jpm-2022-0201
Journal of Perinatal Medicine; Ozdemir O, Aksoy F et. al.

Jul 1st, 2022 - To evaluate the relationship between prenatal ultrasonography (USG) and fetal autopsy findings. Among 453 pregnancy terminations performed because of fetal anomalies on prenatal USG, 54 with skeletal dysplasia on fetal autopsy were included in thi...

Comprehensive literature review on the prevalence of comorbid conditions in patients wi...
https://doi.org/10.1016/j.bone.2022.116472
Bone Stender M, Pimenta JM et. al.

Jun 22nd, 2022 - Achondroplasia (ACH) is a rare, genetic condition and is the most common skeletal dysplasia resulting in disproportionate short stature and numerous multi-systemic comorbidities. As we enter an era of new treatment options which may impact comorbi...

A registry of achondroplasia: a 6-year experience from the Czechia and Slovak Republic.
https://doi.org/10.1186/s13023-022-02374-x 10.1111/j.1399-0004.1977.tb01274.x 10.1136/jmg.16.2.140 10.1136/jmg.23.4.328 10.1002/ajmg.a.32485 10.1093/jb/mvq121 10.1097/GIM.0b013e3181daae9b 10.1002/mgg3.96 10.1074/jbc.M109.094086 10.1006/dbio.1993.1040 10.1093/hmg/8.1.35 10.1016/j.cellsig.2008.10.006 10.1016/j.bbamcr.2014.03.011 10.1016/j.bbadis.2014.12.020 10.1002/humu.21636 10.1002/ajmg.a.31919 10.1097/BRS.0b013e3181574286 10.1016/S0140-6736(07)61090-3 10.1136/adc.2010.189092 10.1002/ajmg.1320590412 10.1007/s12519-016-0051-9 10.1007/s11914-017-0347-2 10.1378/chest.97.4.877 10.1016/j.ijporl.2005.07.016 10.1186/s13023-020-01584-5 10.1186/s13023-021-01725-4 10.1002/ajmg.1320200219 10.1186/s13023-019-1247-6 10.1002/ajmg.a.40528 10.1097/DBP.0b013e3181c72052 10.1016/j.ymgme.2007.06.014 10.1056/NEJMoa1813446 10.1016/S0140-6736(20)31541-5 10.1007/s00392-016-1025-6 10.3390/ijerph15081644 10.1016/j.berh.2007.12.008 10.2105/AJPH.2003.025734 10.1016/j.ajhg.2011.12.017 10.1016/S0022-3476(85)80501-1 10.1136/jmg.35.9.705 10.1159/000439334 10.1097/HJH.0000000000002570 10.1186/s13023-019-1171-9
Orphanet Journal of Rare Diseases; Pesl M, Verescakova H et. al.

Jun 17th, 2022 - Achondroplasia (ACH) is one of the most prevalent genetic forms of short-limbed skeletal dysplasia, caused by gain-of-function mutations in the receptor tyrosine kinase FGFR3. In August 2021, the C-type natriuretic peptide (CNP) analog vosoritide ...

Thoracolumbar stenosis and neurologic symptoms: Quantitative MRI in achondroplasia.
https://doi.org/10.1111/jon.13015
Journal of Neuroimaging : Official Journal of the America... Calandrelli R, Pilato F et. al.

Jun 13th, 2022 - Whole-spine magnetic resonance imaging (MRI) studies, to identify structural abnormalities associated with the development of symptomatic spinal stenosis in achondroplasia. Forty-two subjects with achondroplasia were grouped into four age-related ...

see more →

Drugs  1 results see all →

Clinicaltrials.gov  30 results

A Study Of Safety, Tolerability And Effectiveness Of Recifercept In Children With Achondroplasia
https://clinicaltrials.gov/ct2/show/NCT04638153

May 23rd, 2022 - This is a phase 2 randomized, 3 arm (3 active doses of Recifercept), parallel group dose finding study of safety, tolerability, PK and efficacy The total number of participants is 63 in 2 age straified cohorts of 0-2 years and 6-10 years old. The ...

A Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone in Children With Achondroplasia
https://clinicaltrials.gov/ct2/show/NCT05353192

Apr 29th, 2022 - To Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone in Children with Achondroplasia

Registry for Patients With Achondroplasia / Hypochondroplasia (OMPR-Ach/Hy)
https://clinicaltrials.gov/ct2/show/NCT05328050

Apr 28th, 2022 - This registry is a observational, single-center study designed to collect clinical data on patients with achondroplasia and hypochondroplasia.

Observational Study Investigating Clinical & Anthropometric Characteristics of Children With Achondroplasia.
https://clinicaltrials.gov/ct2/show/NCT03794609

Apr 18th, 2022 - This is a registry study in children with achondroplasia, age 0-10 years, to be conducted at multiple clinical centers in several countries. Information collected will include in anthropometric characteristics, related symptoms, tests, & treatment...

Prospective Clinical Assessment Study in Children With Achondroplasia (ACH)
https://clinicaltrials.gov/ct2/show/NCT04035811

Apr 8th, 2022 - This is a long-term, multi-center, observational study in children 2.5 to 10 years with achondroplasia (ACH). The objective is to evaluate growth, ACH-related medical complications and treatments of study participants. No study medication will be ...

see more →

News  19 results

Review of New Drugs That May Be Used During Pregnancy
https://www.medscape.com/viewarticle/972789

Apr 27th, 2022 - In 2021, the Food and Drug Administration approved 50 new drugs, but 24 will not be described here because they would probably not be used in pregnancy. The 24 are Aduhelm (aducanumab) to treat Alzheimer’s disease; Azstarys (serdexmethylphenidate ...

Review of new drugs that may be used during pregnancy
https://www.mdedge.com/obgyn/article/254158/obstetrics/review-new-drugs-may-be-used-during-pregnancy
Gerald G. Briggs, BPharm, FCCP

Apr 26th, 2022 - In 2021, the Food and Drug Administration approved 50 new drugs, but 24 will not be described here because they would probably not be used in pregnancy. The 24 are Aduhelm (aducanumab) to treat Alzheimer’s disease; Azstarys (serdexmethylphenidate.

FDA Approves Vosoritide for Children With Achondroplasia
https://www.medscape.com/viewarticle/963412

Nov 22nd, 2021 - The US Food and Drug Administration (FDA) has approved vosoritide (Voxzogo) daily injection for the treatment of children with achondroplasia, the most common form of human dwarfism. The indication is for children aged 5 years and older who have a...

FDA OKs First Drug for Most Common Form of Dwarfism
https://www.medpagetoday.com/endocrinology/growthdisorders/95786

Nov 19th, 2021 - The FDA granted accelerated approval to the first drug to spur growth in kids with the most common form of dwarfism, the agency announced on Friday. Vosoritide (Voxzogo), a once-daily injectable treatment, is indicated for children 5 years and old...

Europe Approves Biomarin Drug for Type of Dwarfism in Region's First
https://www.medscape.com/viewarticle/957381

Aug 30th, 2021 - (Reuters) - U.S.-based Biomarin Pharmaceutical Inc said on Friday the European Commission cleared its treatment for one of the most common forms of dwarfism, the first such approval in the region for a therapy to treat achondroplasia. The approval...

see more →

Patient Education  2 results see all →